InflaRx sees signals of efficacy in vilobelimab pyoderma gangrenosum trial
Tweet Send to a Friend
InflaRx N.V. (NASDAQ: IFRX) reported additional analyses of its Phase 3 trial for vilobelimab in pyoderma gangrenosum, which was terminated ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
